MEDICAL

Nanoform Launches Technology that can form Biological Nanoparticles as Small as 50 nm and New Near-Term Business Target for 2021

Nanoform | November 27, 2020

Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner.

As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle formation technology gives want to improving the potential outcomes and probabilities of growing better medications for patients and it extends Nanoform's  reach into the growing biological market. The technology is in its beginning phases of advancement and a patent application has recently been filed with the US Patent Office for the technology. As of today, Nanoform has two non-GMP lines on the biologics side notwithstanding the eight CESS® little atom nanoparticle innovation non-GMP lines.

Spotlight

Robert Gadimian explains how drug development and drug discovery is done. What the different clinical study Phases are and how and why clinical studies are done.He explain the probability of success for the clinical studies and the drug getting to the market.


Other News
MEDICAL

ABC Opens Commercial MEL BioSurfactant Production in Irvine, CA

ABC | May 19, 2022

Advanced BioCatalytics (ABC) is pleased to announce the opening of our new biosurfactant commercial pilot plant in Irvine California. The plant reflects the successful collaboration of the ABC R&D team and Dr. Wenjie Xia, professor of Microbiology at Nankai University in Tianjin China. The commercial pilot plant is the first step in commercial scale up of new glycolipid (biosurfactants) and is the first plant to produce commercial quantities of mannosylerythritol lipids (MEL) in North America. ABC pioneered the use of microbiology to produce metabolites and sustainable chemistry in 1996. Our products are used in water treatment, the energy sector, for agriculture uses, and in personal and home care applications. By using microbiology, we can create natural alternatives to petrochemicals. For our production we upcycle waste feed stocks such as used vegetable oils or other sources of bio-waste material. As a result, our chemistry also offers an alternative to plant based materials which have the unfortunate reliance on certain plant species which are contributing to global deforestation and destruction of biodiversity. The MEL material can be used in a variety of ways in the homecare and personal care sectors. MEL is free of 1,4 dioxane, mild on the skin, and produces minimal foam. This superfatting agent is ideal for delivering moisture in personal care products and can be used along with anionic and amphoteric surfactants for improved efficacy. The addition of MEL production compliments ABC's rhamnolipid and BioSS RL fermactant production. About Advanced BioCatalytics: Advanced BioCatalytics is an industrial biotechnology company that leverages its innovative Fermactant technology for applications in the Home and Personal Care, Energy, Agriculture, and Wastewater markets. These products have demonstrated the ability to be highly cost-effective, without depending on harmful chemistries such as caustics, acids or dangerous solvents, which can be harmful to the user and/or the environment. Advanced BioCatalytics was founded in 1996 and we are excited to be introducing a new technology that will change the future performance, and cost, of the world's cleaning products.

Read More

MEDICAL

Slingshot Biosciences, Inc. Partners With Cambridge Bioscience to Distribute Synthetic Cells Throughout United Kingdom and Ireland

Slingshot | June 16, 2022

SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that bring consistent precision and accurate control to replace inconsistent blood and tissue controls for use in flow cytometry and other biotech markets, today announced they have extended their distribution channel through a new agreement with Cambridge Bioscience, a UK-based specialist distributor of life science research tools. The agreement entitles Cambridge Bioscience to the right to distribute and resell Slingshot Bio’s products in the United Kingdom and Ireland. Through Cambridge Bioscience’s network of customers, Slingshot Bio will be able to establish its presence in the United Kingdom and Ireland market with the well-established presence and expertise of Cambridge Bioscience which has been selling into flow cytometry for many years. Cambridge Bioscience’s network will provide us with the market penetration needed to reach our full sales potential. Slingshot Biosciences has considered many distribution partners and we are confident that Cambridge Bioscience’s extensive knowledge in the field, prominent presence, and large customer base will help us leverage our position in the flow cytometry market.” Jeffrey Kim, CEO & Founder. About Slingshot Biosciences, Inc. Founded in 2012, Slingshot Biosciences is a fast-growing life sciences company with a platform technology and paradigm-shifting mission to make synthetic cells the gold standard for all cell-based applications—including diagnostics, and adoptive cell therapy development and instrument calibration.

Read More

INDUSTRIAL IMPACT

Angel Yeast Partners with PhaBuilder to Open PHA Factory

Angel Yeast | July 27, 2022

Angel Yeast a globally listed yeast and yeast extract manufacturer, has inked an agreement with Bejing PhaBuilder Biotechnology Co., Ltd in Yichang, Hubei province to build a large manufacturing base for polyhydroxyalkanoates (PHA) in the city. The pair will set up a joint venture company to drive the application of synthetic biology in the biotechnology industry. PHA is a polyester produced naturally by microorganisms. The biodegradable and biocompatible properties of PHA make it highly sought-after in fields such as biomedical material and biodegradable packaging material. "This collaboration with PhaBuilder marks a milestone and a significant step forward for Angel Yeast in synthetic biology. At Angel Yeast, we are very keen on innovation and exploration of new landscapes in the industry. This project is also part of our efforts to be an international and professional biotechnology company," Tao Xiong, chairman of Angel Yeast He added that the partnership is expected to forge a new venture in bioeconomy, fuel innovation in synthetic biology, and drive the expansion of the global market. Guoqiang Chen, the founder of PhaBuilder, added that by working with Angel Yeast on the initiative, major inroads have been made in converting technology breakthroughs into industrial programs for synthetic biology. "The new production line of PHA with the capacity of 30,000 tons will certainly bring more advanced technologies, new services and products for the industry and consumers. It will also create a 'greener' lifestyle. We are thrilled to see it happen," said Chen. In addition to synthetic biology, Angel Yeast has also been exploring cutting-edge development in biological agriculture. According to the company, it will be engaged in a project to produce animal feed through biological fermentation. Angel Yeast will invest some 120 million yuan to build the manufacturing center with an annual capacity of 50,000 tons. The project is estimated to start in August 2022 and to be completed in September the next year. One highlight of the project is that it uses Distillers' Dried Grains with Solubles (DDGS) as one raw material to produce yeast culture products. As a new category, yeast culture products will diversify the company's animal nutrition products lineup. About Angel Yeast Founded in 1986, Angel Yeast Co., Ltd specializes in the production of yeast and yeast derivatives. Its product range includes baker's yeast and ingredients, Chinese dim sum and seasoning, savory yeast extract, human health, animal nutrition, plant nutrition, distilled spirits and biofuels, microbial nutrition, and enzymes.

Read More

MEDICAL

Fluent BioSciences and NanoCellect announce joint collaboration to improve resolution of single-cell RNA sequencing analysis of rare cell populations

Fluent BioSciences | June 18, 2022

Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, and NanoCellect Biomedical, Inc., a leader in the development and manufacturing of innovative and affordable solutions for cell sorting, jointly announced a collaboration to improve resolution and efficiency of single-cell RNA sequencing (scRNA-seq) analysis of rare cell populations. Single-cell researchers are increasingly requiring scalable, flexible and accessible workflow solutions, and the combination of cell sorting on the NanoCellect platform followed by scRNA-seq on a novel, instrument-free platform for scRNA-seq based on Pre-templated Instant Partitions (PIPseq™) from Fluent can be a highly efficient solution for a wide range of single cell applications across oncology, immunology and neuroscience. For single-cell sequencing to truly become mainstream researchers need benchtop solutions that fit their diverse experimental needs rather than compromising the science with complex, expensive, and inflexible platforms. I am very pleased that Fluent and NanoCellect are able to leverage and combine the unique advantages of our respective technologies to expand the use of single-cell RNA sequencing for rare cell populations." Sepehr Kiani Ph.D., co-founder, and CEO of Fluent BioSciences. Reliable and reproducible sample preparation is critically important to the scRNAseq workflow, NanoCellect's WOLF® and WOLF G2® Cell Sorters can function as a valuable step in the scRNA-seq workflow by isolating only cells of interest while removing dead cells and debris, thus improving scRNA-seq resolution of rare cell populations of interest and overall sequencing data quality." Jose Morachis, Ph.D., President and co-founder at NanoCellect. About Fluent BioSciences Fluent's mission is to accelerate the understanding of single-cell biology through accessible, affordable, and scalable solutions for every researcher. Our breakthrough PIPseq™ technology enables extremely sensitive and unbiased preparation of proteins and nucleic acids for a broad range of applications. About NanoCellect Biomedical NanoCellect is committed to empowering every scientist to make discoveries one cell at a time, by ensuring high cell viability required to advance cell-based research. We develop and deliver microfluidic based solutions that are affordable, compact, and easy-to-use. Our expanding portfolio of instruments and consumables enable biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, antibody discovery, and basic research.

Read More

Spotlight

Robert Gadimian explains how drug development and drug discovery is done. What the different clinical study Phases are and how and why clinical studies are done.He explain the probability of success for the clinical studies and the drug getting to the market.

Resources